The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
The role of TH17 cells in multiple sclerosis: Therapeutic implications
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) where immunopathology is thought to be mediated by myelin-reactive CD4+ T helper (TH) cells. The TH cells most commonly implicated in the pathogenesis of the disease are of TH1 and TH17 lineage, which are defined by the production of interferon-γ and interleukin-17, respectively. Moreover, there is emerging evidence for the involvement of TH17.1 cells, which share the hallmarks of TH1 and TH17 subsets. In this review, we summarise current knowledge about the potential role of TH17 subsets in the initiation and progression of the disease and put a focus on their response to approved immunomodulatory MS drugs. In this regard, TH17 cells are abundant in peripheral blood, cerebrospinal fluid and brain lesions of MS patients, and their counts and inflammatory mediators are further increased during relapses. Fingolimod and alemtuzumab induce a paramount decrease in central memory T cells, which harbour the majority of peripheral TH17 cells, while the efficacy of natalizumab, dimethyl fumarate and importantly hematopoietic stem cell therapy correlates with TH17.1 cell inhibition. Interestingly, also CD20 antibodies target highly inflammatory TH cells and hamper TH17 differentiation by IL-6 reductions. Moreover, recovery rates of TH cells best correlate with long-term efficacy after therapeutical immunodepletion. We conclude that central memory TH17.1 cells play a pivotal role in MS pathogenesis and they represent a major target of MS therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells
Kleinewietfeld, M., Manzel, A., Titze, J., Kvakan, H., Yosef, N., Linker, R. A., Muller, D. N., & Hafler, D. A. (2013) · Nature · doi:10.1038/nature11868 · Cited by 1,394
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M., & Fugger, L. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070690 · Cited by 1,187
Fate mapping of IL-17-producing T cells in inflammatory responses
Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., et al. (2011) · Nature Immunology · doi:10.1038/ni.1993 · Cited by 1,176
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1
Wu, C., Yosef, N., Thalhamer, T., Zhu, C., Xiao, S., Kishi, Y., Regev, A., & Kuchroo, V. K. (2013) · Nature · doi:10.1038/nature11984 · Cited by 1,022
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., & Mills, K. H. G. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04143.x · Cited by 945
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationThe Balance of Th17 versus Treg Cells in Autoimmunity
Lee, G. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030730 · Cited by 857
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
Matusevicius, D., Kivisäkk, P., He, B., Kostulas, N., Özenci, V, Fredrikson, S., & Link, H. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500206 · Cited by 751
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells
Koenen, H. J. P. M., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M. H., & Joosten, I. (2008) · Blood · doi:10.1182/blood-2008-01-133967 · Cited by 736
for the Multiple Sclerosis Genetics Group, Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop, A., Caillier, S. J., Ban, M., Goris, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2103 · Cited by 657
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O’Connor, R. A., Anderton, S. M., Bar-Or, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111675 · Cited by 649
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
Preferential recruitment of interferon‐γ–expressing T H 17 cells in multiple sclerosis
Kebir, H., Ifergan, I., Alvarez, J. I., Bernard, M., Poirier, J., Arbour, N., Duquette, P., & Prat, A. (2009) · Annals of Neurology · doi:10.1002/ana.21748 · Cited by 551
Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis
Fife, B. T., Huffnagle, G. B., Kuziel, W. A., & Karpus, W. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.6.899 · Cited by 511
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.011 · Cited by 508
Muraro, P. A., Douek, D. C., Packer, A., Chung, K., Guenaga, F. J., Cassiani-Ingoni, R., Campbell, C., Memon, S., Nagle, J. W., Hakim, F. T., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041679 · Cited by 502
IL-17–producing human peripheral regulatory T cells retain suppressive function
Beriou, G., Costantino, C. M., Ashley, C. W., Yang, L., Kuchroo, V. K., Baecher-Allan, C., & Hafler, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-183251 · Cited by 483
Cayrol, R., Wosik, K., Berard, J. L., Dodelet-Devillers, A., Ifergan, I., Kebir, H., Haqqani, A. S., Kreymborg, K., Krug, S., Moumdjian, R., et al. (2008) · Nature Immunology · doi:10.1038/ni1551 · Cited by 444
Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis
Brucklacher-Waldert, V., Stuerner, K., Kolster, M., Wolthausen, J., & Tolosa, E. (2009) · Brain · doi:10.1093/brain/awp289 · Cited by 431
Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R., & Weaver, C. T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415675112 · Cited by 427
The immunogenetics of multiple sclerosis: A comprehensive review
Hollenbach, J. A., & Oksenberg, J. R. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.06.010 · Cited by 420
Class II HLA interactions modulate genetic risk for multiple sclerosis
the International Multiple Sclerosis Genetics Consortium (2015) · Nature Genetics · doi:10.1038/ng.3395 · Cited by 418
IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
Stritesky, G. L., Yeh, N., & Kaplan, M. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.5948 · Cited by 417
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
Gran, B., Zhang, G.-X., Yu, S., Li, J., Chen, X.-H., Ventura, E. S., Kamoun, M., & Rostami, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.7104 · Cited by 405
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12
Becher, B., Durell, B. G., & Noelle, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15751 · Cited by 386
T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β
Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., & Novelli, F. (2009) · Annals of Neurology · doi:10.1002/ana.21652 · Cited by 375
Serada, S., Fujimoto, M., Mihara, M., Koike, N., Ohsugi, Y., Nomura, S., Yoshida, H., Nishikawa, T., Terabe, F., Ohkawara, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802218105 · Cited by 349
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12
Becher, B., Durell, B. G., & Noelle, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215751 · Cited by 346
Hale, G., Xia, M., Tighe, H. P., Dyer, M. J. S., & Waldmann, H. (1990) · Tissue Antigens · doi:10.1111/j.1399-0039.1990.tb01767.x · Cited by 328
Weber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A. J., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 318
Neuhaus, O., Farina, C., Yassouridis, A., Wiendl, H., Then Bergh, F., Dose, T., Wekerle, H., & Hohlfeld, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7452 · Cited by 299
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
Schulze-Topphoff, U., Varrin-Doyer, M., Pekarek, K., Spencer, C. M., Shetty, A., Sagan, S. A., Cree, B. A. C., Sobel, R. A., Wipke, B. T., Steinman, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603907113 · Cited by 293
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400118 · Cited by 289
Th17 Cells in Immunity and Autoimmunity
Bedoya, S. K., Lam, B., Lau, K., & Larkin, J. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/986789 · Cited by 282
Maier, L. M., Lowe, C. E., Cooper, J., Downes, K., Anderson, D. E., Severson, C., Clark, P. M., Healy, B., Walker, N., Aubin, C., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000322 · Cited by 245
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Giovannoni, G., & Schmierer, K. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0676 · Cited by 241
Christensen, J. R., Börnsen, L., Ratzer, R., Piehl, F., Khademi, M., Olsson, T., Sørensen, P. S., & Sellebjerg, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057820 · Cited by 240
Zhang, J., Ke, K.-F., Liu, Z., Qiu, Y.-H., & Peng, Y.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075786 · Cited by 233
IFN-β Inhibits Human Th17 Cell Differentiation
Ramgolam, V. S., Sha, Y., Jin, J., Zhang, X., & Markovic-Plese, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803227 · Cited by 229
van Langelaar, J., van der Vuurst de Vries, R. M., Janssen, M., Wierenga-Wolf, A. F., Spilt, I. M., Siepman, T. A., Dankers, W., Verjans, G. M. G. M., de Vries, H. E., Lubberts, E., et al. (2018) · Brain · doi:10.1093/brain/awy069 · Cited by 222
Gut microbiome in multiple sclerosis: The players involved and the roles they play
Shahi, S. K., Freedman, S. N., & Mangalam, A. K. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1349041 · Cited by 217
Mills, E. A., Ogrodnik, M. A., Plave, A., & Mao-Draayer, Y. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00005 · Cited by 216
Hedegaard, C. J., Krakauer, M., Bendtzen, K., Lund, H., Sellebjerg, F., & Nielsen, C. H. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02837.x · Cited by 211
Features of Human CD3+CD20+ T Cells
Schuh, E., Berer, K., Mulazzani, M., Feil, K., Meinl, I., Lahm, H., Krane, M., Lange, R., Pfannes, K., Subklewe, M., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600089 · Cited by 200
Peng, H., Guerau-de-Arellano, M., Mehta, V. B., Yang, Y., Huss, D. J., Papenfuss, T. L., Lovett-Racke, A. E., & Racke, M. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.383380 · Cited by 195
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
Mehling, M., Lindberg, R., Raulf, F., Kuhle, J., Hess, C., Kappos, L., & Brinkmann, V. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd64 · Cited by 195
A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders
Kamali, A. N., Noorbakhsh, S. M., Hamedifar, H., Jadidi-Niaragh, F., Yazdani, R., Bautista, J. M., & Azizi, G. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.015 · Cited by 194
The anti-CD20 antibody rituximab reduces the Th17 cell response
van de Veerdonk, F. L., Lauwerys, B., Marijnissen, R. J., Timmermans, K., Di Padova, F., Koenders, M. I., Gutierrez-Roelens, I., Durez, P., Netea, M. G., van der Meer, J. W. M., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30314 · Cited by 180
Wu, Q., Wang, Q., Mao, G., Dowling, C. A., Lundy, S. K., & Mao-Draayer, Y. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601532 · Cited by 177
The role of diet in multiple sclerosis: A review
Esposito, S., Bonavita, S., Sparaco, M., Gallo, A., & Tedeschi, G. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1303016 · Cited by 175
dos Passos, G. R., Sato, D. K., Becker, J., & Fujihara, K. (2016) · Mediators of Inflammation · doi:10.1155/2016/5314541 · Cited by 171
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Self-citationZhang, X., Tao, Y., Chopra, M., Ahn, M., Marcus, K. L., Choudhary, N., Zhu, H., & Markovic-Plese, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301926 · Cited by 163
Basdeo, S. A., Cluxton, D., Sulaimani, J., Moran, B., Canavan, M., Orr, C., Veale, D. J., Fearon, U., & Fletcher, J. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600737 · Cited by 161
Garris, C. S., Wu, L., Acharya, S., Arac, A., Blaho, V. A., Huang, Y., Moon, B. S., Axtell, R. C., Ho, P. P., Steinberg, G. K., et al. (2013) · Nature Immunology · doi:10.1038/ni.2730 · Cited by 160
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
Kowarik, M. C., Pellkofer, H. L., Cepok, S., Korn, T., Kümpfel, T., Buck, D., Hohlfeld, R., Berthele, A., & Hemmer, B. (2011) · Neurology · doi:10.1212/wnl.0b013e3182143564 · Cited by 159
The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis
Paulissen, S. M. J., van Hamburg, J. P., Dankers, W., & Lubberts, E. (2015) · Cytokine · doi:10.1016/j.cyto.2015.02.002 · Cited by 155
Schneider‐Hohendorf, T., Rossaint, J., Mohan, H., Böning, D., Breuer, J., Kuhlmann, T., Groß, C. C., Flanagan, K., Sorokin, L. M., Vestweber, D., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140540 · Cited by 155
The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis
Smolders, J., Peelen, E., Thewissen, M. M., et al. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.02.009 · Cited by 153
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells
Sweeney, C. M., Lonergan, R., Basdeo, S. A., Kinsella, K., Dungan, L. S., Higgins, S. C., Kelly, P. J., Costelloe, L., Tubridy, N. J., Mills, K. H. G., et al. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.03.007 · Cited by 152
Darlington, P. J., Touil, T., Doucet, J.-S., Gaucher, D., Zeidan, J., Gauchat, D., Corsini, R., Kim, H. J., Duddy, M., Jalili, F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23784 · Cited by 152
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
Groß, C. C., Schulte‐Mecklenbeck, A., Klinsing, S., Posevitz‐Fejfár, A., Wiendl, H., & Klotz, L. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000183 · Cited by 148
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
Kivisäkk, P., Healy, B. C., Viglietta, V., Quintana, F. J., Hootstein, M. A., Weiner, H. L., & Khoury, S. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8266f · Cited by 147
Th17 and Cognitive Impairment: Possible Mechanisms of Action
Cipollini, V., Anrather, J., Orzi, F., & Iadecola, C. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00095 · Cited by 146
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Gingele, S., Jacobus, T. L., Konen, F. F., Hümmert, M. W., Sühs, K., Schwenkenbecher, P., Ahlbrecht, J., Möhn, N., Müschen, L. H., Bönig, L., et al. (2018) · Cells · doi:10.3390/cells8010012 · Cited by 143
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
von Essen, M. R., Ammitzbøll, C., Hansen, R. H., Petersen, E. R., McWilliam, O. H., Marquart, H. V., Damm, P., & Sellebjerg, F. T. (2018) · Brain · doi:10.1093/brain/awy301 · Cited by 138
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells
Kara, E. E., McKenzie, D. R., Bastow, C. R., Gregor, C. E., Fenix, K. A., Ogunniyi, A. D., Paton, J. C., Mack, M., Pombal, D. R., Seillet, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9644 · Cited by 136
Montes, M., Zhang, X., Berthelot, L., Laplaud, D. A., Brouard, S., Jin, J., Rogan, S. C., Armao, D. M., Jewells, V. L., Soulillou, J., et al. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.030 · Cited by 134
Diaz, G. M., Hupperts, R., Fraussen, J., & Somers, V. A. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.07.001 · Cited by 128
Interferon beta induces T-helper 2 immune deviation in MS
Kozovska, M., Hong, J., Zang, Y. C. Q., Li, S., Rivera, V. M., Killian, J. M., & Zhang, J. Z. (1999) · Neurology · doi:10.1212/wnl.53.8.1692 · Cited by 111
Sato, T., Tachibana, K., Nojima, Y., D'Avirro, N., & Morimoto, C. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.6.2938 · Cited by 110
Claes, N., Fraussen, J., Stinissen, P., Hupperts, R., & Somers, V. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00642 · Cited by 109
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
Rommer, P. S., & Zettl, U. K. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1446944 · Cited by 109
Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis
Calvo‐Barreiro, L., Eixarch, H., Montalbán, X., & Espejo, C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.019 · Cited by 104
Ziemssen, T., & Thomas, K. (2017) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722706 · Cited by 102
Self-citationTh17 cells in central nervous system autoimmunity
Sie, C., Korn, T., & Mitsdoerffer, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.03.009 · Cited by 100
Aharoni, R., Eilam, R., Stock, A. D., Vainshtein, A., Shezen, E., Gal, H., Friedman, N., & Arnon, R. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.04.022 · Cited by 97
The IL-17 Differentiation Pathway and Its Role in Transplant Outcome
Serody, J. S., & Hill, G. R. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.001 · Cited by 92
Larochelle, C., Lécuyer, M., Alvarez, J. I., Charabati, M., Saint‐Laurent, O., Ghannam, S., Kébir, H., Flanagan, K., Yednock, T. A., Duquette, P., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24415 · Cited by 88
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
Li, Z., Richards, S., Surks, H. K., Jacobs, A., & Panzara, M. A. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13208 · Cited by 87
Sporici, R. A., & Issekutz, T. B. (2010) · European Journal of Immunology · doi:10.1002/eji.200939975 · Cited by 86
Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
Ghadiri, M., Rezk, A., Li, R., Evans, A., Luessi, F., Zipp, F., Giacomini, P. S., Antel, J. P., & Bar‐Or, A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000340 · Cited by 84
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
Serpero, L. D., Filaci, G., Parodi, A., Battaglia, F., Kalli, F., Brogi, D., Mancardi, G., Uccelli, A., & Fenoglio, D. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9465-5 · Cited by 83
Darlington, P. J., Stopnicki, B., Touil, T., Doucet, J.-S., Fawaz, L. M., Roberts, M. E., Boivin, M., Arbour, N., Freedman, M. S., Atkins, H. L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00834 · Cited by 82
Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis: In Search of Biomarkers
Alvermann, S., Hennig, C., Stüve, O., Wiendl, H., & Stangel, M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.395 · Cited by 81
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
Mercanti, S. F. D., Rolla, S., Cucci, A., Bardina, V., Cocco, E. E., Vladić, A., Soldo-Butković, S., Habek, M., Adamec, I., Horáková, D., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000194 · Cited by 81
Diaz, G. M., Fraussen, J., Wijmeersch, B. V., Hupperts, R., & Somers, V. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-26519-w · Cited by 78
Paroni, M., Maltese, V., De Simone, M., Ranzani, V., Larghi, P., Fenoglio, C., Pietroboni, A. M., De Riz, M. A., Crosti, M. C., Maglie, S., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.11.045 · Cited by 77
Peripheral blood biomarkers in multiple sclerosis
D’Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., & Margutti, P. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.07.014 · Cited by 77
Potential mechanisms of action related to the efficacy and safety of cladribine
Baker, D., Pryce, G., Herrod, S. S., & Schmierer, K. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.02.018 · Cited by 76
Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
Thomas, K., Eisele, J., Rodriguez-Leal, F. A., Hainke, U., & Ziemssen, T. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000228 · Cited by 75
Self-citationHolley, J. E., Bremer, E., Kendall, A. C., de Bruyn, M., Helfrich, W., Tarr, J. M., Newcombe, J., Gutowski, N. J., & Eggleton, P. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.06.001 · Cited by 71
Cossburn, M., Harding, K. E., Ingram, G., El‐Shanawany, T., Heaps, A. G., Pickersgill, T. P., Jolles, S. R. A., & Robertson, N. P. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b5927 · Cited by 68
Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis
Wasko, N. J., Nichols, F. C., & Clark, R. B. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102430 · Cited by 68
Begum-Haque, S., Sharma, A., Kasper, I. R., Foureau, D., Mielcarz, D. W., Haque, A., & Kasper, L. H. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.07.018 · Cited by 67
Thomas, K., Sehr, T., Proschmann, U., Rodriguez-Leal, F. A., Haase, R., & Ziemssen, T. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0817-6 · Cited by 66
Self-citationLi, Y., Zhang, S., Ma, X., Xue, Y.-L., Gao, C., & Li, X. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.003 · Cited by 63
IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis
Zhang, X., Tao, Y., Chopra, M., Dujmović, I., Jin, J., Tang, Y., Drulovic, J. S., & Markovic‐Plese, S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401680 · Cited by 62
Martín-Saavedra, F. M., González‐García, C., Bravo, B., & Ballester, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.006 · Cited by 61
S1P1 deletion differentially affects TH17 and Regulatory T cells
Eken, A., Duhen, R., Singh, A. K., Fry, M., Buckner, J. H., Kita, M., Bettelli, E., & Oukka, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-13376-2 · Cited by 59
Immunopathology alters Th17 cell glucocorticoid sensitivity
Banuelos, J., Cao, Y., Shin, S. C., & Lu, N. Z. (2016) · Allergy · doi:10.1111/all.13051 · Cited by 58
Cunill, V., Massot, M., Clemente, A., Calles, C., Andreu, V., Núñez, V., López-Gómez, A., Díaz, R. M., Jiménez‐León, M. R., Pons, J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01097 · Cited by 55
D’Amico, E., Zanghì, A., Gastaldi, M., Patti, F., Zappia, M., & Franciotta, D. M. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.05.003 · Cited by 53
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice
Gu, S. M., Park, M. H., Yun, H. M., Han, S., Oh, K. W., Son, D. J., Yun, J. S., & Hong, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.8097 · Cited by 52
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis
Thomas, K., Proschmann, U., & Ziemssen, T. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1373093 · Cited by 52
Self-citationBuzzard, K. A., Broadley, S., & Butzkueven, H. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012665 · Cited by 51
Benkert, T. F., Dietz, L., Hartmann, E., Leich, E., Rosenwald, A., Serfling, E., Buttmann, M., & Berberich‐Siebelt, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052208 · Cited by 50
Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis
Wu, Q., Mills, E. A., Wang, Q., Dowling, C. A., Fisher, C., Kirch, B., Lundy, S. K., Fox, D. A., Mao‐Draayer, Y., & the AMS04 Study Group (2020) · JCI Insight · doi:10.1172/jci.insight.134251 · Cited by 50
Sellner, J., & Rommer, P. S. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102492 · Cited by 50
Self-citationTeixeira, B., Bittencourt, V. C. B., Ferreira, T. B., Kasahara, T. M., Barros, P. O., Alvarenga, R. M. P., Hygino, J., de Andrade, R. M., Andrade, A. F. B., & Bento, C. A. M. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.012 · Cited by 47
Zhang, X., & Markovic‐Plese, S. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2010.04.020 · Cited by 46
Christensen, J. R., Börnsen, L. S., Ratzer, R. L., Piehl, F., Khademi, M., Olsson, T. P., ̧rensen, P. S. S., & Sellebjerg, F. T. (2013) · PLoS ONE · doi:10.1371/annotation/b4e623eb-4950-48d9-8d85-8d70426d95a3 · Cited by 46
Teriflunomide treatment reduces B cells in patients with MS
Gandoglia, I., Ivaldi, F., Laroni, A., Benvenuto, F., Solaro, C. M., Mancardi, G., de Rosbo, N. K., & Uccelli, A. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000403 · Cited by 44
Hu, Y., Nie, H., Yu, H.-H., Qin, C., Wu, L., Tang, Z.-P., & Tian, D. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.011 · Cited by 44
Main features of human T helper 17 cells
Annunziato, F., Cosmi, L., Liotta, F., Maggi, E., & Romagnani, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12075 · Cited by 42
Prinz, M., & Kalinke, U. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.06.001 · Cited by 41
du Pasquier, R., Pinschewer, D., & Merkler, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0160-8 · Cited by 40
Fallis, R. J., Raine, C. S., & McFarlin, D. E. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90039-8 · Cited by 38
Liu, M., Hu, X., Wang, Y., Peng, F., Yang, Y., Chen, X., Lu, Z., & Zheng, X. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01158.x · Cited by 37
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
Ward, L. A., Lee, D. S. W., Sharma, A. K., Wang, A. A., Naouar, I., Xianjie, I., Pikor, N. B., Nuesslein‐Hildesheim, B., Ramaglia, V., & Gommerman, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.132522 · Cited by 37
Ferreira, T. B., Hygino, J., Barros, P. O., Teixeira, B., Kasahara, T. M., Linhares, U. C., Lopes, L. M., Vasconcelos, C. C. F., Alvarenga, R. M. P., Wing, A. C., et al. (2014) · Immunology · doi:10.1111/imm.12334 · Cited by 35
Hansen, R. H., Chow, H. H., Christensen, J. R., Sellebjerg, F. T., & von Essen, M. R. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101451 · Cited by 35
de Bruyn, M., Wiersma, V. R., Wouters, M. C. A., Samplonius, D. F., Klip, H. G., Helfrich, W., Nijman, H. W., Eggleton, P., & Bremer, E. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.999536 · Cited by 34
Accumulation and therapeutic modulation of 6-sulfo LacNAc + dendritic cells in multiple sclerosis
Thomas, K., Dietze, K., Wehner, R., Metz, I., Tumani, H., Schultheiß, T., Günther, C., Schäkel, K., Reichmann, H., Brück, W., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000033 · Cited by 32
Self-citationDisease activity return after natalizumab cessation in multiple sclerosis
Rasenack, M., & Derfuss, T. J. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1168295 · Cited by 30
Induction of systemic TNFα in Natalizumab‐treated multiple sclerosis
Khademi, M., Stol, D., Olsson, T. P., & Wallström, E. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02037.x · Cited by 27
Kalra, S., Lowndes, C., Durant, L., Strange, R., Al-Araji, A. H., Hawkins, C., & Curnow, J. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217319899695 · Cited by 26
Teniente‐Serra, A., Grau‐López, L., Mansilla, M. J., Fernández, M. A., Condins, A. E., Ramo-Tello, C. M., & Martínez-Cáceres, E. M. (2016) · Autoimmunity · doi:10.3109/08916934.2016.1138271 · Cited by 25
Haas, J., Würthwein, C., Korporal‐Kuhnke, M., Viehöver, A., Jarius, S., Ruck, T., Pfeuffer, S., Meuth, S. G., & Wildemann, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01204 · Cited by 24
Akgün, K., Blankenburg, J., Marggraf, M., Haase, R., & Ziemssen, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00056 · Cited by 24
Self-citationMansilla, M. J., Navarro‐Barriuso, J., Presas‐Rodríguez, S., Teniente‐Serra, A., Quirant‐Sánchez, B., Ramo-Tello, C. M., & Martínez-Cáceres, E. M. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13142 · Cited by 21
Myelin-reactive B cells exacerbate CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner
Fazazi, M. R., Doss, P. M. I. A., Pereira, R., Fudge, N., Regmi, A., Joly-Beauparlant, C., Akbar, I., Yeola, A. P., Mailhot, B., Baillargeon, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49259-0 · Cited by 21
Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment
Bühler, U., Fleischer, V., Luessi, F., Rezk, A., Belikan, P., Graetz, C., Gollan, R., Wolf, C., Lutz, J., Bar‐Or, A., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516658559 · Cited by 20
Trenova, A. G., Slavov, G. S., Manova, M. G., Draganova-Filipova, M., Mateva, N. G., Miteva, L. D., & Stanilova, S. A. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1303843 · Cited by 19
Barrau, M. A., Montalbán, X., Sáez-Torres, I., Brieva, L., Barberà, N., & Martínez-Cáceres, E. M. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00357-x · Cited by 18
Li, Z., Chen, X., Chen, Y., Li, H., Yu, J., Li, Y., Zhu, W., Xie, Y., Tian, Y., Su, W., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113645 · Cited by 18
Sehr, T., Akgün, K., Proschmann, U., Bucki, R., Żendzian‐Piotrowska, M., & Ziemssen, T. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01812-x · Cited by 15
Self-citationOehrl, S., Olaru, F., Kunze, A., Maas, M., Pezer, S., Schmitz, M., & Schäkel, K. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.06.016 · Cited by 12
Fazazi, M. R., Doss, P. M. I. A., Pereira, R., Fudge, N. J., Regmi, A., Joly-Beauparlant, C., Akbar, I., Yeola, A. P., Mailhot, B., Baillargeon, J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/721696 · Cited by 1
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Ge, L., Liu, S., Li, S., Yang, J., Hu, G., Xu, C., & Song, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016578 · Cited by 187
Th17 cells and inflammation in neurological disorders: Possible mechanisms of action
Shi, Y., Wei, B., Li, L., Wang, B., & Sun, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932152 · Cited by 108
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
“Th17 cells secrete IL-17 (including IL-17A and IL-17F), IL-21, and IL-22, and GM-CSF, which are essential mediators of CNS inflammation [56].”
Metadata
- Authors
- Moser, T., Akgün, K., Proschmann, U., Sellner, J., & Ziemssen, T.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 19
- Issue
- 10
- Pages
- 102647
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W3048887029
- Cited by
- 302
- References
- 157
- FWCI
- 19.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.